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Abstract The objective of this study was to assess the
efficacy and tolerability of YM155, a survivin suppressor,
in combination with docetaxel, compared with docetaxel
alone in patients with HER2-negative metastatic breast
cancer. This phase II, multicenter, open-label, 2-arm study
randomized patients (C18 years) with histologically or
cytologically confirmed stage IV HER2-negative meta-
static breast cancer and C1 measurable lesion, to receive
docetaxel alone or docetaxel plus YM155. The primary
endpoint was progression-free survival (PFS). Secondary
endpoints included objective response rate (ORR), overall
survival (OS), duration of response (DOR), clinical benefit
rate (CBR), time to response (TTR), biomarker assessment,
and analysis of circulating tumor cells. Patients were
women diagnosed with HER2-negative breast cancer; most
had received prior drug therapies. The median PFS was
8.4 months with YM155 plus docetaxel (n = 50) and
10.5 months with docetaxel alone (n = 51; HR 1.53; 95 %
CI 0.83, 2.83; P = 0.176). No statistically significant dif-
ferences were observed for secondary endpoints, although
slightly greater OS (630 vs 601 days; P = 0.768), CBR
(84.3 vs 82.0 %; P = 0.855), DOR, and TTR were
observed with docetaxel alone compared with YM155 plus
docetaxel, whereas ORR was similar (25.5 vs 26.0). The
most common TEAEs observed with YM155 plus doce-
taxel compared with docetaxel alone were neutropenia
(83.3 vs 84.3 %), alopecia (62.5 vs 52.9 %), fatigue (50 vs
41.2 %), and nausea (37.5 vs 41.2 %). Although YM155 is
a novel drug that suppresses survivin, YM155 plus doce-
taxel exhibited no statistically significant differences in
endpoints compared with docetaxel alone. The combina-
tion regimen was well tolerated.
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Introduction
Breast cancer is the most common potentially fatal form of
cancer in women and is the leading cause of death from
cancer in women worldwide [1]. It is estimated that there
will be approximately 235,000 new cases of invasive breast
cancer and more than 40,000 breast cancer deaths in the
United States in 2014 [2]. The majority of patients will be
diagnosed with early stage disease [3], which is amenable
to curative treatment with surgical care and/or radiation
[4]; however, 6–10 % of patients will present with meta-
static breast cancer [5], and up to 30 % of all patients may
ultimately develop metastatic disease [6].
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While metastatic breast cancer generally is incurable,
systemic therapy can provide meaningful prolongation of
survival and palliation of the distressing symptoms of
cancer [7, 8]. The choice of systemic therapy is increas-
ingly determined by biological markers predictive of
response to targeted therapy. Patients with hormone
receptor positive disease will frequently benefit from
endocrine therapies [9]. When the nearly inevitable
development of resistance to endocrine therapy occurs
[10], these patients can still derive benefit from cytotoxic
chemotherapy [11]. Patients whose cancer has an alteration
(usually an amplification) of the HER2 gene derive sub-
stantial benefit from anti-HER2 therapeutics such as trast-
uzumab given in combination with chemotherapy or
endocrine therapy [12].
Approximately 15 % of patients have tumors that do not
express the estrogen or progesterone receptors, and do not
have altered HER-2 [9]. There are currently no markers
predictive of response for patients with these ‘‘triple neg-
ative’’ tumors, and conventional cytotoxic chemotherapy
remains the standard of care [11]. Unfortunately, prognosis
remains poor due to high rates of relapse and chemore-
sistance in this subset of breast cancer patients [13]. New
molecularly targeted systemic therapies for triple negative
breast cancers (TNBC) are urgently needed.
One such candidate target molecule is survivin, a
member of the ‘‘inhibitor of apoptosis protein’’ family that
contributes to increased proliferation and resistance to
apoptosis in tumor cells [14]. Overexpression of survivin
has been demonstrated in metastatic breast cancer com-
pared with normal breast tissue [15]. A recent meta-ana-
lysis found that increased expression of survivin was
significantly associated with unfavorable overall survival
(OS) in patients with breast cancer [16].
YM155 is a small molecular suppressor of survivin.
Continuous infusion of YM155 significantly reduced tumor
size and the incidence of spontaneous metastasis, as well as
prolonged survival, in a mouse model of metastatic TNBC
[17]. In vitro studies demonstrated that inhibition of
apoptosis by survivin required interaction with microtu-
bules [18], providing a powerful rationale for the study of
survivin together with anti-microtubule agents such as
taxanes. YM155 in combination with the microtubule-tar-
geted agent docetaxel induced greater apoptosis compared
with either agent alone, resulting in complete tumor
regression in a mouse TNBC xenograft model [19]. The
results of a phase I study indicated that YM155 was well
tolerated with manageable toxicities in patients with
advanced solid tumors, including breast cancer, that were
refractory to standard therapy [20]. Additionally, findings
from an open-label, single-arm, single-center study of
YM155 plus docetaxel in patients with advanced hormone
refractory prostate cancer and other tumors showed
responses in a few patients with breast cancer, supporting
the design and execution of the present study [21].
The objective of the current phase II study was to assess
the effects of YM155 in combination with docetaxel
compared with docetaxel alone on progression-free sur-




This was a phase II, multicenter, open-label, randomized,
2-arm study (NCT01038804) conducted in the United
States, Europe, and Russia. Local institutional review
boards and independent ethics committees, or both,
approved the study protocol and informed consent forms
before use. The study was conducted in accordance with
the International Conference on Harmonization Guidelines
for Good Clinical Practice, the European Clinical Trial
Directive, and applicable laws and regulations. Each




Patients aged C18 years with histologically or cytologi-
cally confirmed stage IV HER2-negative metastatic breast
cancer and C1 measurable lesion (RECIST criteria, version
1.1) were eligible for enrollment. HER2-negative breast
cancer was defined as negative fluorescence in situ
hybridization (FISH), 0 or 1? immunohistochemistry
(IHC), or IHC 2? with negative FISH. Patients had an
Eastern Cooperative Oncology Group performance status
B1 at baseline. In general, prior first-line chemotherapy for
metastatic breast cancer was not permitted. However, prior
cytotoxic therapy was permitted if it was administered in
the neoadjuvant or adjuvant setting C3 weeks before
baseline. Patients with prior docetaxel treatment were eli-
gible if they had no evidence of recurrent disease within
12 months of completing treatment. Prior treatment with a
kinase inhibitor or hormonal therapy also was permitted if
administered C4 and C2 weeks, respectively, before
baseline, and prior palliative radiation therapy was allowed
if completed C2 weeks before baseline. For a brief period,
the protocol was amended to enroll patients who had pre-
viously received first-line chemotherapy, but this was
revised back to the original criteria of no prior therapy for
metastatic disease based upon preclinical data that sug-
gested that YM155 was a p-glycoprotein substrate.
172 Breast Cancer Res Treat (2015) 149:171–179
123
Exclusion criteria
Patients were excluded if they had hypersensitivity to
docetaxel or polysorbate 80; major surgery, open biopsy, or
significant traumatic injury within 28 days before baseline
or anticipated need for major surgery during the study;
neuropathy grade C2 at baseline; inadequate marrow at
baseline; inadequate hepatic function and renal function, or
both, at baseline; known brain or leptomeningeal metastasis;
known immunodeficiency virus, hepatitis B surface antigen,
or hepatitis C antibody; or significant and/or uncon-
trolled cardiac, renal, hepatic, or other systemic disorders or
significant psychological conditions at baseline.
Treatment regimen
One cycle was considered 21 days and was divided into a
7-day treatment period followed by a 14-day (Arm A;
YM155 plus docetaxel) or a 20-day (Arm B; docetaxel
alone) observation period. YM155 was administered by
continuous infusion at a dose of 5 mg/m2/day for 168 h. The
YM155 infusion was initiated on day 1 within 1 h of com-
pletion of docetaxel dosing using a portable infusion pump
to administer study drug through a dedicated central line,
port, or peripherally inserted central catheter. Dose reduction
of YM155 to 3.6 mg/m2/day was permitted at the investi-
gator’s discretion in patients with a grade 3 or 4 adverse
event (AE), with the exception of weight loss or gain,
anorexia, alopecia, and fatigue. Infusion of YM155 and
docetaxel was interrupted until the AE resolved to grade B1
or returned to baseline, and infusion of YM155 could then
be restarted at the original dose of 5 mg/m2/day or reduced
to 3.6 mg/m2/day at the discretion of the investigator.
Docetaxel [22] was administered by intravenous infusion
for 1 h on day 1 every 21-day cycle at a dose of 75 mg/m2 in
patients treated with YM155 plus docetaxel and 75 or
100 mg/m2 in patients treated with docetaxel alone at the
discretion of the investigator. Dose reduction of docetaxel to
75 mg/m2 was permitted at the discretion of the investigator
in patients with febrile neutropenia or an absolute neutrophil
count\500 cells/mm3 lasting[1 week and in patients with
severe or cumulative cutaneous reactions. In the event that
these AEs were ongoing, further dose reduction of docetaxel
to 55 mg/m2 or discontinuation of docetaxel was permitted
at the discretion of the investigator. In patients with a grade
3 or 4 AE, with the exception of peripheral neuropathy,
weight loss or gain, anorexia, alopecia, and fatigue, doce-
taxel treatment was interrupted until the AE resolved to
grade B1 or returned to baseline and then could be restarted
at 75 for patients receiving 100 mg or 55 mg/m2 for patients
receiving 75 mg/m2 at the time of the AE. Discontinuation
of docetaxel treatment was required in patients with grade 3
or 4 neuropathy.
Retreatment criteria
The following criteria must have been met before a patient
began the next cycle of treatment: no evidence of disease
progression based on radiological and/or clinical assess-
ments, and any YM155- and/or docetaxel-related toxicity
must have either resolved to a grade of B1 or returned to
baseline level.
Assessments
The primary efficacy endpoint was PFS. Subgroup analyses
of PFS were performed according to TNBC or hormone
receptor positive status. The secondary efficacy endpoints
assessed included objective response rate (ORR), OS, dura-
tion of response (DOR), clinical benefit rate (CBR), and time
to response (TTR). Patients were evaluated by computed
tomography, magnetic resonance imaging, or both, every
6 weeks (cycle 1 and 2) within 5 days of the initial docetaxel
infusion and every 12 weeks thereafter. Objective tumor
assessments were determined using RECIST, version 1.1.
Blood samples were collected from all patients during
screening and cycles 1–3 to assess biomarkers, including
caspase-cleaved cytokeratin 18 (M30 Apoptosense
ELISA, PEVIVA AB, Broma, Sweden), a tumor apoptosis
marker. Blood samples were collected during cycles 1 and
2 for analysis of circulating tumor cells.
Safety and tolerability assessments included AEs and
clinical laboratory evaluations.
Statistical analyses
The efficacy analyses were conducted on the full analysis
set (FAS) and per protocol (PP) set. The FAS included all
patients randomized into the study and was considered the
primary analysis set. The PP set included all randomized
patients who were administered C1 dose of their assigned
study regimen, had histologically or cytologically proven
adenocarcinoma of the breast that was HER2-negative, had
no known brain or leptomeningeal metastasis, had no his-
tory of other malignancy within 5 years before the first
dose of YM155, except for treated basal or squamous cell
carcinoma of the skin or in situ cervical cancer, and did not
have major protocol deviations.
Demographic data and baseline disease and treatment
characteristics were summarized using descriptive statis-
tics. The median PFS, including subgroup analyses of PFS,
OS, and DOR were estimated using the Kaplan–Meier
method reported with corresponding 95 % CI. PFS and OS
were analyzed between treatment arms using a two-sided
log-rank test stratified by prior taxane therapy and triple
negative status (a = 0.05). PFS also was compared
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between treatment arms using the hazard ratio, corre-
sponding 95 % CI, and P value from the stratified Cox
proportional hazards regression model. ORR and CBR
were compared between treatment arms using the stratified
Cochran-Mantel-Haenszel test, and the difference in
response rates and corresponding 95 % CIs were estimated
using large sample methods and unpooled variance esti-
mates. The TTR was summarized using descriptive
statistics.
Approximately 100 patients (randomized in a 1:1 ratio)
stratified by prior taxane therapy and triple negative status
(yes or no for both) were required to observe 67 PFS events
(progressive disease or death). The sample size had 55 %
power to detect a true hazard ratio of 0.60 (median PFS of
10 vs 6 months).
Safety was assessed in all patients who received C1
dose of study regimen and summarized using descriptive
statistics or frequency distributions, as appropriate.
Results
Baseline demographics and characteristics
Of 119 patients screened, 101 were enrolled and random-
ized to treatment and 99 received the drug. At baseline, all
patients were women diagnosed with HER2-negative
metastatic breast cancer, and the majority had received
prior drug therapies, principally in the adjuvant or neoad-
juvant setting (Table 1).
Table 1 Baseline
characteristics (full analysis set)
NOS not otherwise specified
a HER2, estrogen, and
progesterone receptors







Female 50 (100) 51 (100) 101 (100)
Median age, years (range) 57.0 (34–79) 55.0 (25–77) 55.0 (25–79)
Race, n (%)
White 47 (94.0) 48 (94.1) 95 (94.1)
Black or African American 1 (2.0) 1 (2.0) 2 (2.0)
Asian 1 (2.0) 0 1 (1.0)
Other 1 (2.0) 2 (3.9) 3 (3.0)
Subtype at diagnosis, n (%)
Ductal 37 (74.0) 33 (64.7) 70 (69.3)
Lobular 4 (8.0) 8 (15.7) 12 (11.9)
Paget’s disease and infiltrating 2 (4.0) 0 2 (2.0)
Medullary, NOS 0 1 (2.0) 1 (1.0)
Papillary 0 1 (2.0) 1 (1.0)
Other 7 (14.0) 8 (15.7) 15 (14.9)
Tumor grade, n (%)
Grade 1 1 (2.0) 2 (3.9) 3 (3.0)
Grade 2 24 (48.0) 19 (37.3) 43 (42.6)
Grade 3 15 (30.0) 16 (31.4) 31 (30.7)
Unknown 10 (20.0) 14 (27.5) 24 (23.8)
Tumor receptor status, n (%)
Triple receptor negativea 13 (26.0) 12 (23.5) 25 (24.8)
Estrogen receptor status
Positive 34 (68.0) 35 (68.6) 69 (68.3)
Negative 13 (26.0) 14 (27.5) 27 (26.7)
Unknown 3 (6.0) 2 (3.9) 5 (5.0)
Progesterone receptor status
Positive 22 (44.0) 33 (64.7) 55 (54.5)
Negative 23 (46.0) 14 (27.5) 37 (36.6)
Unknown 5 (10.0) 4 (7.8) 9 (8.9)
Prior drug therapy, n (%) 43 (86.0) 44 (86.3) 87 (86.1)
Prior taxane therapy, n (%) 11 (22.0) 9 (17.6) 20 (19.8)
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Treatment exposure
Patients in the YM155 plus docetaxel group completed a
median of 6.0 cycles of YM155 infusion; 4 (8.3 %) patients
experienced YM155 dose reduction, and 8 (16.7 %) patients
experienced an interruption. In addition, patients in this arm
received a median of 6.0 cycles and a cumulative total dose
of 679.0 mg of docetaxel infusion; 9 (18.8 %) patients
experienced a dose reduction and no patients an interruption.
Patients in the docetaxel arm completed a median of
7.43 cycles and received a median cumulative total dose of
827.5 mg of docetaxel infusion; 12 (23.5 %) patients
experienced a dose reduction and no patients experienced
an interruption.
Primary and secondary endpoints
The median PFS was 8.4 months in patients treated with
YM155 plus docetaxel compared with 10.5 months in
patients administered docetaxel alone. This difference was
not statistically significant (P = 0.172; Table 2). Kaplan–
Meier plots of PFS are presented in Fig. 1a. The docetaxel
Table 2 Analysis of primary
and secondary efficacy
endpoints for the full analysis
population
CBR clinical benefit rate, DOR
duration of response, FAS full
analysis set, NA not available,
ORR objective response rate, OS
overall survival, PFS
progression-free survival
* At the time of data cutoff,
median DOR had not been
reached
Clinical outcome YM155 ? Docetaxel
(FAS, n = 50)
Docetaxel




Median (95 % CI) PFS, days 251.0 (172, 333) 315.0 (202, 433) 0.172
HR (95 % CI) 1.53 (0.83, 2.83) 0.176
Secondary efficacy endpoints
ORR, n (%) 13 (26.0) 13 (25.5) 0.987
CBR, n (%) 41 (82.0) 43 (84.3) 0.855
Median OS, days 601.0 630.0 0.768
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Fig. 1 Kaplan-Meier plots of a progression-free survival, b overall survival, c duration of response, and d time to response in the full analysis
population
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arm demonstrated slightly better secondary endpoints com-
pared with the YM155 plus docetaxel arm, but no statisti-
cally significant differences between the treatment arms
were observed (Table 2; Fig. 1b–d). In addition, median
PFS, OS, and DOR values were similar between the FAS
and PP populations, with no significant differences between
treatment arms for the PP population (data not shown).
Biomarker analyses for the presence of caspase-cleaved
cytokeratin 18, a specific marker for epithelial cell apop-
tosis, suggested a slightly higher percentage of tumor
apoptosis with YM155 plus docetaxel (31.4 %) compared
with docetaxel alone (18.3 %). Circulating tumor cells
were very low and no differences could be shown between
Table 3 Treatment-emergent adverse events occurring in C10 % in
either treatment arm (safety analysis population)





Neutropenia 40 (83.3) 43 (84.3)
Leukopenia 13 (27.1) 17 (33.3)
Anemia 13 (27.1) 6 (11.8)
Febrile neutropenia 11 (22.9) 5 (9.8)
Lymphopenia 3 (6.3) 6 (11.8)
Nonhematologic
Alopecia 30 (62.5) 27 (52.9)
Fatigue 24 (50.0) 21 (41.2)
Nausea 18 (37.5) 21 (41.2)
Dyspnea 16 (33.3) 7 (13.7)
Diarrhea 11 (22.9) 10 (19.6)
Edema peripheral 9 (18.8) 12 (23.5)
Neuropathy peripheral 7 (14.6) 12 (23.5)
Stomatitis 11 (22.9) 8 (15.7)
Decreased appetite 8 (16.7) 9 (17.6)
Asthenia 7 (14.6) 8 (15.7)
Constipation 6 (12.5) 8 (15.7)
Cough 6 (12.5) 8 (15.7)
Dysgeusia 5 (10.4) 9 (17.6)
Headache 8 (16.7) 5 (9.8)
Mucosal inflammation 8 (16.7) 5 (9.8)
Pyrexia 8 (16.7) 5 (9.8)
Arthralgia 8 (16.7) 4 (7.9)
Back pain 9 (18.8) 2 (3.9)
Bone pain 4 (8.3) 7 (13.7)
Nail disorder 6 (12.5) 5 (9.8)
Urinary tract infection 6 (12.5) 5 (9.8)
Pain in extremity 4 (8.3) 6 (11.8)
Insomnia 6 (12.5) 3 (5.9)
Peripheral sensory neuropathy 3 (6.3) 6 (11.8)
Myalgia 2 (4.2) 6 (11.8)
Oropharyngeal pain 5 (10.4) 0
Table 4 Treatment-emergent grade C3 adverse events (safety ana-
lysis population)





Neutropenia 19 (39.6) 12 (23.5)
Leukopenia 6 (12.5) 8 (15.7)
Febrile neutropenia 8 (16.7) 4 (7.8)
Lymphophenia 3 (6.3) 4 (7.8)
Dyspnea 3 (6.3) 1 (2.0)
Pneumonia 2 (4.2) 2 (3.9)
Central line infection 2 (4.2) 1 (2.0)
Palmar-plantar
erythrodysasthesia syndrome
1 (2.1) 2 (3.9)
Deep vein thrombosis 2 (4.2) 0




Peripheal neuropathy 0 2 (3.9)
Anemia 1 (2.1) 1 (2.0)
Asthenia 1 (2.1) 1 (2.0)
Atrial fibrillation 1 (2.1) 1 (2.0)
Bone pain 1 (2.1) 1 (2.0)
Catheter-related infection 1 (2.1) 1 (2.0)
Cellulitis 1 (2.1) 1 (2.0)
Dehydration 1 (2.1) 1 (2.0)
Decreased white blood cell
count
1 (2.1) 1 (2.0)
Syncope 1 (2.1) 1 (2.0)
Atrial thrombosis 1 (2.1) 0
Clostridium difficile colitis 1 (2.1) 0
Decreased appetite 1 (2.1) 0




Excoriation 1 (2.1) 0
Hypoalbuminemia 1 (2.1) 0




Mucosal inflammation 1 (2.1) 0
Nail disorder 1 (2.1) 0
Pericarditis 1 (2.1) 0
Platelet disorder 1 (2.1) 0
Polyneuropathy 1 (2.1) 0
Pulmonary embolism 1 (2.1) 0
Respiratory failure 1 (2.1) 0
Stomatitis 1 (2.1) 0
Superior vena cava occlusion 1 (2.1) 0
Thrombosis 1 (2.1) 0
Vascular access complication 1 (2.1) 0
Back pain 0 1 (2.0)
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the two treatment arms. However, for both analyses, the
sample sizes were very small and no statistical correlations
could be made.
Safety and tolerability
All patients in the safety analysis population (n = 99)
experienced C1 TEAE (Table 3). The most common TE-
AEs in both treatment groups were neutropenia, alopecia,
fatigue, and nausea. Most TEAEs were grade 3 or 4, and
the events reported in the YM155 plus docetaxel arm were
judged more often to be possibly or probably related to
study drug, whereas none of the events in the docetaxel
alone arm were judged to be possibly or probably related
(Tables 3, 4).
The most common drug-related TEAEs in the YM155
plus docetaxel arm were neutropenia (n = 18 [37.5 %]),
fatigue (n = 13 [27.1 %]), and febrile neutropenia (n = 9
[18.8 %]). A total of 14 (29.2 %) patients administered
YM155 plus docetaxel and 9 (17.6 %) patients adminis-
tered docetaxel alone experienced a TEAE leading to study
discontinuation. TEAEs leading to study discontinuation
that occurred in C2 patients in a treatment arm were febrile
neutropenia and leukopenia (each n = 2 [4.2 %]) in
patients administered YM155 plus docetaxel and fluid
retention, palmar-plantar erythrodysesthesia syndrome, and
peripheral neuropathy (each n = 2 [3.9 %]) in patients
administered docetaxel alone.
Serious AEs (SAEs) were experienced by 25 (52.1 %)
patients administered YM155 plus docetaxel and 17
(33.3 %) administered docetaxel alone (Table 5). SAEs that
occurred in C5 % of patients in either treatment group
included febrile neutropenia, neutropenia, and pneumonia
(Table 5). A total of 56 (56.6 %) patients died during the
study; 28 (58.3 %) patients were treated with YM155 plus
docetaxel and 28 (54.9 %) patients received docetaxel alone.
Most of the deaths (87.5 %) were attributed to breast cancer.
In patients administered YM155 plus docetaxel, two deaths
were attributed to hepatic failure, one to a cerebrovascular
accident, one to general state degradation, and the cause of
death in one patient was unknown. In patients who received
docetaxel alone, one death was attributed to sepsis; in one
Table 4 continued




Bronchitis 0 1 (2.0)
Catheter site infection 0 1 (2.0)
Cerebral infarction 0 1 (2.0)
Decreased neutrophil count 0 1 (2.0)
Fatigue 0 1 (2.0)
Fluid retention 0 1 (2.0)
Herpes zoster 0 1 (2.0)
Hydronephrosis 0 1 (2.0)
Hyponatremia 0 1 (2.0)
Hypophosphatemia 0 1 (2.0)
Increased blood glucose 0 1 (2.0)
Infective arthritis 0 1 (2.0)
Neck pain 0 1 (2.0)
Pain in extremity 0 1 (2.0)
Paresthesia 0 1 (2.0)
Pelvic pain 0 1 (2.0)
Peripheral edema 0 1 (2.0)
Pleurisy 0 1 (2.0)
Pyrexia 0 1 (2.0)
Rash 0 1 (2.0)
Wound infection 0 1 (2.0)
Grade 4
Neutropenia 21 (43.8) 30 (58.8)
Leukopenia 5 (10.4) 4 (7.8)
Febrile neutropenia 2 (4.2) 1 (2.0)
Decreased neutrophil count 1 (2.1) 1 (2.0)
Decreased white blood cell
count
1 (2.1) 1 (2.0)
Pulmonary embolism 1 (2.1) 1 (2.0)
Catheter sepsis 1 (2.1) 0
Fatigue 1 (2.1) 0
Increased blood creatinine 1 (2.1) 0
Infection 1 (2.1) 0
Metastases to central nervous
system
0 1 (2.0)
Sepsis 1 (2.1) 0
Septic shock 1 (2.1) 0
Thoracic vertebral fracture 1 (2.1) 0
Grade 5
Breast cancer 1 (2.1) 0
Cerebrovascular accident 1 (2.1) 0
Table 5 Most common serious adverse events regardless of causality
occurring in C5 % of patients (safety analysis population)






Any SAE 25 (52.1) 17 (33.3) 42 (42.4)
Hematologic
Febrile neutropenia 10 (20.8) 4 (7.8) 14 (14.1)
Neutropenia 5 (10.4) 4 (7.8) 9 (9.1)
Nonhematologic
Pneumonia 3 (6.3) 2 (3.9) 5 (5.1)
SAE serious adverse event
Breast Cancer Res Treat (2015) 149:171–179 177
123
patient, the cause of death was unknown. None of the deaths
were related to the study medications.
Three patients discontinued treatment due to abnor-
malities in laboratory values (increased gamma-glutamyl-
transferase, increased blood urea nitrogen and blood
creatinine, and platelet disorder/thrombopathy); all of these
abnormalities were considered possibly or probably related
to YM155. Other laboratory findings were generally not
clinically significant. No cardiac safety signals were
detected during the study.
Discussion
Findings from this study of patients with HER2-negative
metastatic breast cancer treated with YM155 in combina-
tion with docetaxel exhibited no statistically significant
differences in the primary endpoint of PFS or secondary
endpoints compared with patients administered docetaxel
alone. The combination of YM155 plus docetaxel was well
tolerated. The most common drug-related TEAEs in the
YM155 plus docetaxel arm were expected and included
neutropenia, fatigue, and febrile neutropenia. Renal failure
was reported in a previous study with YM155 and was
considered to be related to YM155 [23]. In the present
study, one patient in the combination arm discontinued
with elevated blood urea nitrogen and creatinine levels that
were deemed related to study drug; these events resolved
11 and 25 days following onset, respectively.
YM155 was administered as a continuous intravenous
infusion for 168 h in a 21-day cycle. Preclinical data
suggest that bolus infusion may increase the risk for renal
and/or cardiovascular toxicity. Although continuous infu-
sion is more time-consuming and may be less convenient,
the need for continuous infusion did not affect recruitment
in the present study, and patients experienced no difficulty
with drug administration over a long period of time.
An urgent unmet need for additional therapeutic options
in patients with TNBC exists because of their high risk of
relapse and poor long-term prognosis [24, 25]. A positive
outcome was expected from this study because YM155 is a
novel drug that suppresses survivin at both the mRNA and
protein levels [26]; survivin is a protein that is associated
with decreased apoptosis and has been shown to be more
highly expressed in metastatic breast cancer compared with
normal breast tissue [27]. YM155 is also highly distributed
to tumor tissues relative to normal plasma [26]. Although
these preclinical data provide a good rationale for evalu-
ating YM155 in breast cancer, findings from the present
study demonstrated that YM155 plus docetaxel exhibited
no statistically significant differences in PFS, ORR, OS,
DOR, or CBR compared with patients administered doce-
taxel alone.
However, this study also had some limitations, including
the lack of formal pharmacokinetic interaction analysis
between YM155 and docetaxel. In addition, the limited
amount of biomarker data available leaves open the ques-
tion of whether there is a patient population more likely to
benefit from the combination of YM155 with docetaxel.
Improved availability and use of biomarkers could help
identify patients with TNBC or other types of cancer who
might benefit from specific inhibition of survivin. Although
development of YM155 in patients with TNBC is not
proceeding, further research into drugs effective at target-
ing the survivin pathway is warranted.
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